![](https://monteverdelaw.com/wp-content/uploads/case-logo/seagen-inc.png)
Seagen, Inc. (NASDAQ: SGEN), relating to its proposed sale to Pfizer Inc. Under the terms of the agreement SGEN shareholders are expected to receive $229.00 in cash per share they own.
Seagen, Inc. (NASDAQ: SGEN), relating to its proposed sale to Pfizer Inc. Under the terms of the agreement SGEN shareholders are expected to receive $229.00 in cash per share they own.